论文部分内容阅读
目的研究普伐他汀对扩张型心肌病心力衰竭(心衰)患者心功能的影响并探讨其可能机制。方法 36例扩张型心肌病心衰患者随机分为普伐他汀治疗组和安慰剂对照组,每组18例,随访12个月,治疗前后检测超声左心室舒张末期内径,射血分数、血清白细胞介素-6,肿瘤坏死因子-α,同型半胱氨酸及血浆脑钠肽水平,并进行比较。结果普伐他汀治疗12个月后,治疗组较对照组左室射血分数增加(P<0.05),血中炎症因子水平下降(P<0.05),左心室舒张末期内径减小(P<0.05)。结论普伐他汀长期治疗能改善扩张型心肌病心衰患者的左室射血分数,机制可能与降低心衰患者血清中的白细胞介素-6,肿瘤坏死因子-α,同型半胱氨酸及血浆脑钠肽水平,从而减轻心室重构有关。
Objective To study the effect of pravastatin on cardiac function in patients with dilated cardiomyopathy with heart failure (HF) and to explore its possible mechanism. Methods Thirty-six patients with heart failure of dilated cardiomyopathy were randomly divided into pravastatin group and placebo group. Eighteen patients in each group were followed up for 12 months. The left ventricular end-diastolic diameter, ejection fraction, serum leukocyte Interleukin-6, tumor necrosis factor-α, homocysteine and plasma brain natriuretic peptide levels, and compared. Results After 12 months of treatment with pravastatin, the left ventricular ejection fraction increased (P <0.05) and the levels of inflammatory cytokines in the treatment group decreased (P <0.05) ). Conclusion Long-term treatment with pravastatin can improve the left ventricular ejection fraction in patients with heart failure due to dilated cardiomyopathy. The mechanism may be related to the decrease of serum interleukin-6, tumor necrosis factor-α, homocysteine and Plasma brain natriuretic peptide levels, thereby reducing ventricular remodeling.